SCHUMER, GILLIBRAND ANNOUNCE OVER $4 MILLION IN RECOVERY ACT FUNDING COMING TO WESTERN NEW YORK FOR HEALTH RESEARCH
Recovery Act Money Through National Institutes of Health Will Support 15 Biomedical Research and Training Projects at Roswell Park Cancer Institute and The University at BuffaloOver $65 Million Coming to Institutions Across New York StateSchumer, Gillibrand: Funding Will Create Jobs, Keep State on Cutting Edge of Research
<![if gte mso 9]>Normal 0 false false false ENUS XNONE XNONE MicrosoftInternetExplorer4 <![endif]><![if gte mso 9]> <![endif]> <![if gte mso 10]><![endif]>
U.S. Senators Charles E. Schumer and Kirsten Gillibrand today announced that the American Recovery and Reinvestment Act (ARRA) will provide a total of $4,180,862 million in funding through the National Institutes of Health (NIH) for biomedical research projects in Western New York. The Roswell Park Cancer Institute will receive $2,231,472 and The University at Buffalo will receive $1,949,390. The ARRA will provide a total of $64,826,308 for projects statewide, including $13,288,446 for those at institutions upstate.
"This funding for biomedical research is a wise investment in the Western New York economy," said Schumer. "Not only will these federal dollars help New York institutions tackle our biggest health issues, but we will be creating research and teaching positions in the region. I will continue to fight for funding to keep our state's worldclass schools and research facilities at the forefront of medicine."
"It is critical that we invest in the lifesaving research at our world class medical facilities in Western New York," said Senator Gillibrand. "Federal funding for this cutting edge research will advance research and treatment while promoting economic growth for New York. I will continue to work with Senator Schumer to make sure New York gets its fair share of federal dollars."
The funding will be broken down as follows:
Roswell Park Cancer Institute
- $491,634 in funding to study innate and adaptive immune response to bacterial infections in COPD patients
- $397,991 in funding to study inflammatory control of lymphocyte trafficking
- $386,285 in funding to study vitamin D analogs for chemoprevention of prostate cancer
- $383,842 in funding to study requirements for normal Rb function in vivo
- $321,845 in funding to study the role of estrogen receptor Alphap53 interaction in resistance to Tamoxifen
- $249,875 in funding to study innate and adaptive immune responses at the respiratory mucosa
The University at Buffalo
- $389,985 in funding to study integration of clinical, genomic and proteomic data using a bioinformatic approach
- $385,377 in funding to study influenza therapy by Aunanorod 5'PPPNS1siRNA/cDNA targeting of bronchial cells
- $380,818 in funding to study protein Arginine Methylation in Trypanosomes
- $277,375 in funding to study drug abuse and impulsivity
- $173,995 in funding to study genetics and biology of M. Catarrhalis LOS in Otitis Media
- $148,552 in funding to study scalable bioprocess for Cardiomyocyte Generation from human embryonic stem cells
- $77,439 in funding to study Kv4.3 Gating Current
- $64,139 in funding to study animal models of Tinnitus, brain imaging and therapy
- $51,710 in funding to study the role of the guide RNA binding protein RBP16 in the bloodstream form of T. brucei
NIH funds biomedical research and research training at more than 3,000 institutions in the fifty states and territories.
# # #
Previous Article Next Article